RxDoctor Payments Data

Charlie Bartlett

Nurse Practitioner · Knoxville, TNNPI 1821022716

Payments from drug & device makers

$3,183in general payments, 2019–2025

Across 126 payments — averaging $25.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$802
  • Collegium Pharmaceutical, Inc.$610
  • Boston Scientific$435
  • Amgen$294
  • AbbVie$214
  • Vertos Medical, Inc.$160
  • plus $667 from 14 others

What the payments were for

  • Travel & lodging$1113%
  • Food & beverage$3,07297%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,183 in reported general payments places this provider in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$143,076
Medicare patients
242
Services billed
2,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate108$53,569
Oxymorphone Hcl ErOxymorphone Hcl93$28,992
OxycontinOxycodone Hcl40$22,421
Oxycodone Hcl877$19,903
BelbucaBuprenorphine Hcl19$17,013
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen517$16,145
MovantikNaloxegol Oxalate27$10,744
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen388$9,904
Lidocaine92$9,271
Gabapentin605$7,810
Naloxone Hcl100$6,306
Morphine Sulfate ErMorphine Sulfate218$5,637
Tizanidine Hcl298$4,016
Diclofenac Sodium109$3,774
Fentanyl21$3,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$610$70,582127 claims
Redhill Biopharma Inc.Movantik$13$10,74427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →